I was at a presentation some time back and Leslie Chong said she had lead a number of purchasing deals when she was at Genentech, her last deal being around $US800m ($AUD1.1Billion).
Leslie and Axel Hoos have an enormous amount of experience on how to maximize the $ amount Pharma will pay.
I believe they are carefully creating a company with a platform that if the science proves up has the potential too disrupt the T Cell market, it’s not just about Her-Vaxx.
These next results are another value enhancing piece in the building block. It’s not short term as the future $ upside could be bloody Big
The executive team are now appropriately aligned with shareholders and the upside for all could be rather disruptive
Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-190
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |